Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - December 2012

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Lanthanum carbonate (Fosrenol®) has been accepted for restricted use as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD). The restriction recommends use as a second-line agent where a non-aluminium and non-calcium phosphate binder is required.

Olmesartan / amlodipine / hydrochlorothiazide (Sevikar HCT®) has been accepted for use in adult patients whose blood pressure is not adequately controlled on the combination of olmesartan and amlodipine taken as dual-component formulation. The recommendation clarifies that "These fixed dose combinations are among many options for the treatment of hypertension, many of which are less expensive".

5-aminolaevulinic acid (Ameluz®) has been accepted for use in the treatment of actinic keratosis of mild to moderate intensity on the face and scalp.

Perampanel (Fycompa®) has been accepted for restricted use in as an adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. The restriction recommends use as a second-line agent in refractory partial onset epilepsy and that it should only be initiated by experienced physicians.

Racecadotril (Hidrasec Infants®, Hidrasec Children®) has been rejected for us as a complementary symptomatic treatment of acute diarrhoea in infants older than three months and in children. The manufacturer failed to make a sufficiently robust clinical and economic case.

Racecadotril (Hidrasec®) has been rejected for symptomatic treatment of acute diarrhoea in adults when causal treatment is not possible. The manufacturer failed to make a submission.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - December 2012' on Email Share 'SMC Update - December 2012' on Delicious Share 'SMC Update - December 2012' on Digg Share 'SMC Update - December 2012' on Facebook Share 'SMC Update - December 2012' on Google+ Share 'SMC Update - December 2012' on reddit Share 'SMC Update - December 2012' on StumbleUpon Share 'SMC Update - December 2012' on Twitter

atomic-wealth

No Comments to “SMC Update - December 2012”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,318 spam comments.

atomic-wealth
fond-illness
summer